Skip to main content
Explore URMC
menu

Leukemia (AML & MDS): Connect® MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Research Question:
What are the patterns of diagnosis, treatment and outcomes including disease progression and survival; what are the patterns for quality of life in patients newly diagnosed with Lower-Risk MDS, Higher-Risk MDS, ICUS or AML and what effect does different treatments have on a patient's disease and on their quality of life?

Basic Study Information

Purpose:
This study is observational. An observational disease registry study means that only information about your disease and medical treatment that your study doctor is already prescribing as part of your standard medical care is collected. Standard medical care is the treatment normally given for a certain condition or illness. You will continue with your standard medical care and continue with any medicines you are now taking, office visits and laboratory testing according to the normal routine practices of your treating or study doctor(s). No additional medication, or payment for medication, is provided as part of this study. There is no investigational drug involved in this study. There will be no additional study visits, procedures, or testing required for this study. We will only collect this information as it relates to the standard medical care you are receiving. If you give your consent to participate in this study, your study doctor will inform your treating doctor(s), if applicable, that you are taking part in this study.

Location: Cancer Center
Study Reference #: ICHR17065

Lead Researcher (Principal Investigator)

Lead Researcher: Jason Mendler

Study Contact Information

Study Coordinator: Brandon DeLorme
Phone: (585) 275-5295
Email: Brandon_Delorme@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Myeloid leukemia, acute

Return to Search